Commentary by Sandeep Mangalmurti MD, JD PGY-2Â
“Pay-for performance†is the broadly encompassing term used to describe recent efforts to restructure physician compensation so that rewards are commensurate to performance. Initially limited to small …
Commentary by Cara Litvin MD, Executive Editor, Clinical Correlations
The sensation of déjà vu was likely very common this week. First, we experienced a flashback to 1994 when we saw OJ in handcuffs …
Commentary by Helen Kourlas, PharmD
On September 17th 2007, the FDA issued an advisory warning healthcare professionals to avoid the use of higher than recommended doses of haloperidol, marketed as Haldol, Haldol Decanoate and …
Commentary by Elizabeth Hackett MD, PGY-3
On July 25th, 2007, the NYC Department of Health released an advisory requesting that all New York City physicians maintain a high index of suspicion for Legionnaires’ disease in …
Commentary by Zackary Berger MD PhD, PGY-2
A recent article in the New York Times publicized changes in Medicare subsidies. In the article’s own words, “Medicare will no longer pay the extra …
Commentary by Henry Tran, MD
There continues to be accumulating evidence of the beneficial effects of statin therapy. Coming on the heels of the SPARCL trial, which demonstrated that high-dose atorvastatin reduces …
Commentary by Mary Vouyiouklis MD, Fellow, and Ann Danoff MD, Director, Division of Endocrinology, Diabetes and Metabolism, NYU Medical CenterÂ
Welcome to Case 2 of our special diabetes series intended to highlight the …
Commentary by Bani Chander MD, PGY-2, and Sergio Obligado MD, Attending Physician, Nephrology
Tumor lysis syndrome (TLS) is characterized by a group of metabolic abnormalities including hyperkalemia, hyperuricemia, and hyperphosphatemia with secondary …